Guidelines for the use of imaging in the management of patients with myeloma
暂无分享,去创建一个
Vicky Goh | Guy Pratt | Majid Kazmi | V. Goh | S. Barrington | G. Pratt | N. Mulholland | Sally Barrington | Nicola Mulholland | M. Kazmi | A. Chantry | M. Streetly | M. Lai | Andrew Chantry | Matthew Streetly | Maggie Lai
[1] Appearance of monoclonal plasma cell diseases in whole‐body magnetic resonance imaging and correlation with parameters of disease activity , 2014, International journal of cancer.
[2] Ji-An Liang,et al. FDG PET or PET/CT for Detecting Intramedullary and Extramedullary Lesions in Multiple Myeloma: A Systematic Review and Meta-analysis , 2012, Clinical nuclear medicine.
[3] R. Fanin,et al. A prospective comparison of 18 F-fluorodeoxyglucose positron emission tomography-computed tomography , magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma , 2007 .
[4] M. Yun,et al. Efficacy of Multidetector Row Computed Tomography of the Spine in Patients With Multiple Myeloma: Comparison With Magnetic Resonance Imaging and Fluorodeoxyglucose-Positron Emission Tomography , 2007, Journal of computer assisted tomography.
[5] Gerhard Glatting,et al. Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience. , 2007, Radiology.
[6] Bang-Bin Chen,et al. Correlation among DCE‐MRI measurements of bone marrow angiogenesis, microvessel density, and extramedullary disease in patients with multiple myeloma , 2012, American journal of hematology.
[7] A. Buck,et al. 18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. , 2014 .
[8] M. Topbaş,et al. Effect of pathologic fractures on survival in multiple myeloma patients: a case control study , 2008, Journal of experimental & clinical cancer research : CR.
[9] M. Reiser,et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? , 2002, Cancer.
[10] C. Collins,et al. Problems monitoring response in multiple myeloma , 2005, Cancer imaging : the official publication of the International Cancer Imaging Society.
[11] W A Murphy,et al. Bone marrow imaging. , 1988, Radiology.
[12] M. Beksac,et al. European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications , 2015, Haematologica.
[13] A. Kahn,et al. Myelomatosis: Fundamentals and Clinical Features , 1971 .
[14] C. Messiou,et al. Whole body diffusion weighted MRI – a new view of myeloma , 2015, British journal of haematology.
[15] M. Dimopoulos,et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease , 2013, Leukemia.
[16] M. Horger,et al. Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography. , 2016, European journal of radiology.
[17] C. Nanni,et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[18] M. Salvatore,et al. 18 F-FDG PET / CT , 99 mTc-MIBI , and MRI in Evaluation of Patients with Multiple Myeloma , 2008 .
[19] Hans Erik Johnsen,et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.
[20] K. Nikolaou,et al. Improved Follow-Up and Response Monitoring of Thoracic Cage Involvement in Multiple Myeloma Using a Novel CT Postprocessing Software: The Lessons We Learned. , 2016, AJR. American journal of roentgenology.
[21] A. Rahmouni,et al. Detection of multiple myeloma involving the spine: efficacy of fat-suppression and contrast-enhanced MR imaging. , 1993, AJR. American journal of roentgenology.
[22] M. Salvatore,et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma , 2008, Journal of Nuclear Medicine.
[23] M. Reiser,et al. Role of MRI for the diagnosis and prognosis of multiple myeloma. , 2005, European journal of radiology.
[24] G. Çeti̇n,et al. The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma , 2011, Skeletal Radiology.
[25] B. Barlogie,et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. , 2009, Blood.
[26] B. Maldague,et al. Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging. , 1998, Radiology.
[27] M. Dimopoulos,et al. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] H. Kauczor,et al. Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease. , 2014, European journal of radiology.
[29] A. Wåhlin,et al. Evaluation of serial bone X-ray examination in multiple myeloma. , 2009, Acta medica Scandinavica.
[30] V. Gulani,et al. Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk. , 2012, The Canadian journal of urology.
[31] C. Nanni,et al. PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma , 2015, Clinical Cancer Research.
[32] L. Moulopoulos,et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] M. Dimopoulos,et al. Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. , 2017, Radiology.
[34] D. Collins,et al. Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility , 2011, European Radiology.
[35] S. Knop,et al. FDG PET/CT depicts cutaneous plasmocytoma. , 2014, Clinical nuclear medicine.
[36] E. Low,et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).
[37] E. Kotter,et al. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey , 2006, European Radiology.
[38] D. Louis,et al. Bone marrow imaging. , 1989, Radiology.
[39] Meic H. Schmidt,et al. Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] A. Buck,et al. FDG-PET / CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation , 2014 .
[41] G. Morgan,et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. , 2015, Blood.
[42] R A Kyle,et al. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma , 2009, Leukemia.
[43] A Ferrant,et al. Vertebral compression fractures in multiple myeloma. Part I. Distribution and appearance at MR imaging. , 1997, Radiology.
[44] M. Attal,et al. Comparison of MRI and computed tomography in the various stages of plasma cell disorders: correlations with biological and histological findings. Myélome-Midi-Pyrénées Group. , 1996, Clinical and experimental rheumatology.
[45] B. Maldague,et al. Magnetic Resonance and Computed Tomography Imaging in Multiple Myeloma , 2001, Seminars in musculoskeletal radiology.
[46] H. Schirrmeister,et al. Positron emission tomography (PET) for staging of solitary plasmacytoma. , 2003, Cancer biotherapy & radiopharmaceuticals.
[47] R. Fanin,et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. , 2011, Blood.
[48] A. Guermazi,et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma , 1999, British journal of haematology.
[49] M. Dimopoulos,et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. , 1992, Hematology/oncology clinics of North America.
[50] P. Pereira,et al. The benefit of using whole‐body, low‐dose, nonenhanced, multidetector computed tomography for follow‐up and therapy response monitoring in patients with multiple myeloma , 2007, Cancer.
[51] S. Barrington,et al. Fluoro‐deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma , 2002, British journal of haematology.
[52] Xiaohu Zhao,et al. Disseminated plasmacytomas in multiple myeloma: atypical presentations on multimodality images, emphasized on PET/CT , 2013, Annals of Hematology.
[53] H. Kauczor,et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. , 2009, Radiology.
[54] S. Salmon,et al. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.
[55] M. Dimopoulos,et al. Risk of disease progression in asymptomatic multiple myeloma. , 1993, The American journal of medicine.
[56] M. Dimopoulos,et al. Multiple myeloma: MR patterns of response to treatment. , 1994, Radiology.
[57] V. Ambrosini,et al. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. , 2008, In vivo.
[58] V. Yu,et al. Letter: Transfusion of fresh blood in the newborn period. , 1974, Lancet.
[59] B. Durie. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. , 2006, European journal of cancer.
[60] Tobias Bäuerle,et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] Margaret Hall-Craggs,et al. Guidelines for the use of imaging in the management of myeloma , 2007, British journal of haematology.
[62] R. Hayes,et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.
[63] O. Awan,et al. Multiple Myeloma Lesion Detection With Whole Body CT Versus Radiographic Skeletal Survey , 2013, Cancer investigation.
[64] R. Kyle,et al. Prevalence and monitoring of oligosecretory myeloma. , 2012, The New England journal of medicine.
[65] R. Walker,et al. Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias , 2012, The Journal of Nuclear Medicine.
[66] D. Blondin,et al. Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma , 2007, European Radiology.
[67] B. Maldague,et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey , 1999, British journal of haematology.
[68] Reinhard Vonthein,et al. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. , 2005, European journal of radiology.
[69] R. Howard,et al. A monoclonal gammopathy precedes multiple myeloma in most patients. , 2009, Blood.
[70] A. Chirindel,et al. Characterizing and Predicting Pathologic Spine Fractures in Myeloma Patients With FDG PET/CT and MR Imaging , 2011, Cancer investigation.
[71] E Terpos,et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma , 2009, Leukemia.
[72] F. Sim,et al. Effect of granulocyte-stimulating factors on marrow of adult patients with musculoskeletal malignancies: incidence and MRI findings. , 2004, AJR. American journal of roentgenology.
[73] M. Dimopoulos,et al. Bone lesions with soft-tissue mass: magnetic resonance imaging diagnosis of lymphomatous involvement of the bone marrow versus multiple myeloma and bone metastases. , 1999, Leukemia & lymphoma.
[74] M. Dimopoulos,et al. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients , 2012, American journal of hematology.
[75] Wolfgang Schima,et al. The skull unfolded: a cranial CT visualization algorithm for fast and easy detection of skull fractures. , 2010, Radiology.
[76] B. Barlogie,et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. , 2013, Blood.
[77] J. Cox,et al. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. , 1998, International journal of radiation oncology, biology, physics.
[78] R W Günther,et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. , 2002, AJR. American journal of roentgenology.
[79] R. Subramaniam,et al. Evolving role of FDG PET/CT in multiple myeloma imaging and management. , 2013, AJR. American journal of roentgenology.
[80] T Hielscher,et al. Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance , 2014, Leukemia.
[81] M. Gore,et al. MAGNETIC RESONANCE IMAGING IN MYELOMA , 1988, The Lancet.
[82] P. Sonneveld,et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma‐related bone disease: a systematic review , 2013, British journal of haematology.
[83] S. Schoenberg,et al. Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy , 2009, Annals of Hematology.
[84] R. Kyle. Monoclonal gammopathy of undetermined significance (MGUS). , 1995, Bailliere's clinical haematology.
[85] G. Morgan,et al. Assessing response of myeloma bone disease with diffusion-weighted MRI. , 2012, The British journal of radiology.
[86] A. Waxman,et al. Whole-body (18)F-FDG PET identifies high-risk myeloma. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[87] P. Moreau,et al. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma , 2008, Haematologica.
[88] Q. Sodji,et al. Management of Metastatic Spinal Cord Compression , 2017, Southern medical journal.
[89] G. Treglia,et al. The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Evaluating the Response to Treatment in Patients with Multiple Myeloma , 2012, International journal of molecular imaging.
[90] H. Brodoefel,et al. Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)? , 2012, Academic radiology.
[91] H. Goldschmidt,et al. Diffusion‐weighted imaging for non‐invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology , 2011, British journal of haematology.
[92] G. Morgan,et al. Guidelines for the diagnosis and management of multiple myeloma 2011 , 2011, British journal of haematology.
[93] R. Fanin,et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. , 2007, Haematologica.
[94] P. Moreau,et al. Multiple myeloma imaging. , 2013, Diagnostic and interventional imaging.
[95] E. Zamagni,et al. The role of imaging techniques in the management of multiple myeloma , 2012, British journal of haematology.
[96] Jian Hou,et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] Christopher J. Hanrahan,et al. Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT. , 2010, Radiographics : a review publication of the Radiological Society of North America, Inc.
[98] F. Trippa,et al. Management of Metastatic Spinal Cord Compression , 2003, Tumori.
[99] G. Åström,et al. MR Imaging of Multiple Myeloma in Tumour Mass Measurement at Diagnosis and during Treatment , 1995, Acta radiologica.
[100] D. Hose,et al. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma , 2012, Haematologica.
[101] Hartmut Goldschmidt,et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. , 2011, Blood.
[102] Y. Nakamoto. Clinical contribution of PET/CT in myeloma: from the perspective of a radiologist. , 2014, Clinical lymphoma, myeloma & leukemia.
[103] Junshik Hong,et al. Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation , 2014, British journal of haematology.
[104] S. Ahuja,et al. Management of metastatic spinal cord compression: awareness of NICE guidance , 2014, European Journal of Orthopaedic Surgery & Traumatology.
[105] Kenneth C. Anderson,et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.
[106] S. Jagannath,et al. State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. , 2014, European journal of radiology.
[107] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.
[108] Konstantin Nikolaou,et al. Improvement of diagnostic confidence for detection of multiple myeloma involvement of the ribs by a new CT software generating rib unfolded images: Comparison with 5- and 1-mm axial images , 2015, Skeletal Radiology.
[109] D. Alexandru,et al. Evaluation and management of vertebral compression fractures. , 2012, The Permanente journal.
[110] B. Line,et al. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma , 2006, Skeletal Radiology.
[111] H. Goldschmidt,et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.
[112] B. Barlogie,et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] M. Reiser,et al. Role of MRI for the diagnosis and prognosis of multiple myeloma. , 2005, European journal of radiology.
[114] S. Sironi,et al. Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM). , 2013, European journal of radiology.
[115] T. Derlin,et al. Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation , 2012, European Radiology.
[116] Christoph Thomas,et al. Dual-energy CT: virtual calcium subtraction for assessment of bone marrow involvement of the spine in multiple myeloma. , 2015, AJR. American journal of roentgenology.
[117] Eric J. W. Visser,et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[118] K. Loke,et al. The Role of PET/CT in the Evaluation of Skeletal Metastases , 2014, Seminars in Musculoskeletal Radiology.
[119] S. Schoenberg,et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. , 2008, AJR. American journal of roentgenology.
[120] A. Surov,et al. Non-osseous incidental findings in low-dose whole-body CT in patients with multiple myeloma. , 2014, The British journal of radiology.